Baudhuin, Linnea M. http://orcid.org/0000-0003-4230-5032
Train, Laura J.
Goodman, Shaun G. http://orcid.org/0000-0001-8068-2440
Lane, Gary E.
Lennon, Ryan J.
Mathew, Verghese
Murthy, Vishakantha
Nazif, Tamim M.
So, Derek Y. F.
Sweeney, John P.
Wu, Alan H. B.
Rihal, Charanjit S.
Farkouh, Michael E.
Pereira, Naveen L.
Funding for this research was provided by:
Foundation for the National Institutes of Health (U01HL128606, U01HL128626, U01HL128606, U01HL128626, U01HL128606, U01HL128626)
Article History
Received: 1 February 2022
Revised: 5 April 2022
Accepted: 11 April 2022
First Online: 21 April 2022
Competing interests
: MEF reports research grants from Amgen, Novartis, and Novo Nordisk. Dr. So reports unrestricted grant support from Spartan Biosciences and Fujimori Kogyo and is on advisory boards for AztraZeneca Canada, Bayer Canada, JAMP/Orimed Pharma, and HLS Therapeutics. SGG reports research grant support and/or speaker/consulting honoraria from: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo/American Regent, Eli Lilly, JAMP Pharma, Pfizer, Servier, Valeo Pharma; and salary support/honoraria from the Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre. The remaining authors have no disclosures to report.